Lewy Bodies (LBs) are distinctive intraneural cytoplasmic inclusions of unknown pathogenesis. They are found in all cases of Parkinson's Disease (PD), and diffuse Lewy body disease (DLBD) (also known as the Lewy body variant of Alzheimer's disease). In addition, LBs are occasionally found in a few other pathological processes. The composition of LBs by direct biochemical methods and their role in these diseases processes remains unknown. Recently we have shown that antibodies raised to purified amyloid extracted from familial amyloidosis, Finnish type (FAF) immunoreact with LBs. This immunoreactivity is specific, as it was absorbed by the purified amyloid proteins and is unaffected by other antigens such as ubiquitin, neurofilament proteins and tubulin which have been shown by immunohistochemical methods to be present in LBs. FAF amyloid has been found to be an aberrant degradation product, starting at position 173, of gelsolin, an actin modulating protein. The amino acid sequence shows heterogeneity at the N-terminus and at position 15, where asparagine substitutes for aspartic acid. At the DNA level, a guanine to adenine transition corresponding to nucleotide 654 of the human gelsolin has been found in all FAF patients tested so far. Commercially available anti- gelsolin antibodies raised to the carboxy-terminus of the molecule (away from the amyloidogenic region) do not immunostain LBs. This raises the possibility that LBs also contain an abnormal fragment of gelsolin that is closer to the amino terminal of the molecule. We plan: (1) To perform an immunohistochemical survey of DLBD, Alzheimer's disease, and Parkinson's disease cases with the anti-FAF antibody, as well as with antibodies to intact gelsolin, fragments and synthetic peptides of different regions of the gelsolin molecule, to evaluate patterns of immunoreactivity and epitope mapping; (2) To characterize the composition of the purified LBs preparation by using Western blotting and direct amino acid sequencing to sequence gelsolin and/or its fragments; (3) To investigate the biological activity of gelsolin isolated from DLBD, PD, AD, and control CSF to see if there are any abnormalities; (4) To clone the gelsolin gene from familial PD patients and screen for any variations; (5) To investigate cerebral spinal fluid from patients with PD, DLBD, other neurodegenerative disorder, controls and AD for the presence of any abnormal gelsolin fragments that could be used as a diagnostic test. Together these studies will expand knowledge about LBs and the role gelsolin plays in their formation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS030455-03
Application #
3417343
Study Section
Special Emphasis Panel (SRC (33))
Project Start
1991-09-30
Project End
1995-09-29
Budget Start
1993-09-30
Budget End
1994-09-29
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
New York University
Department
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012
Baumann, M H; Kallijarvi, J; Lankinen, H et al. (2000) Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides. Biochem J 349:77-84
Soto, C; Golabek, A; Wisniewski, T et al. (1996) Alzheimer's beta-amyloid peptide is conformationally modified by apolipoprotein E in vitro. Neuroreport 7:721-5
Palha, J A; Moreira, P; Wisniewski, T et al. (1996) Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 204:212-4
Wisniewski, T; Frangione, B (1996) Molecular biology of brain aging and neurodegenerative disorders. Acta Neurobiol Exp (Wars) 56:267-79
Golabek, A A; Soto, C; Vogel, T et al. (1996) The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem 271:10602-6
Perini, F; Vidal, R; Ghetti, B et al. (1996) PrP27-30 is a normal soluble prion protein fragment released by human platelets. Biochem Biophys Res Commun 223:572-7
Perini, F; Frangione, B; Prelli, F (1996) Prion protein released by platelets. Lancet 347:1635-6
Wisniewski, T; Lalowski, M; Baumann, M et al. (1996) HB-GAM is a cytokine present in Alzheimer's and Down's syndrome lesions. Neuroreport 7:667-71
Lalowski, M; Golabek, A; Lemere, C A et al. (1996) The ""nonamyloidogenic"" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 271:33623-31
Baumann, M H; Wisniewski, T; Levy, E et al. (1996) C-terminal fragments of alpha- and beta-tubulin form amyloid fibrils in vitro and associate with amyloid deposits of familial cerebral amyloid angiopathy, British type. Biochem Biophys Res Commun 219:238-42

Showing the most recent 10 out of 22 publications